ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Indianapolis, IN, USA:

FT576 in Subjects With Multiple Myeloma

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma...

Enrolling
Multiple Myeloma
Myeloma
Drug: Bendamustine
Drug: FT576 (Allogenic CAR NK cells with BCMA expression)

Phase 1

Fate Therapeutics
Fate Therapeutics

Indianapolis, Indiana, United States and 13 other locations

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Dexamethasone

Phase 2

AbbVie
AbbVie

Indianapolis, Indiana, United States and 31 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Carfilzomib

Phase 3

Celgene
Celgene

Indianapolis, Indiana, United States and 59 other locations

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical ben...

Enrolling
Multiple Myeloma
Drug: Elranatamab

Phase 4

Pfizer
Pfizer

Indianapolis, Indiana, United States and 12 other locations

provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab (PF-06863135)

Phase 2

Pfizer
Pfizer

Indianapolis, Indiana, United States and 77 other locations

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GS...

Enrolling
Multiple Myeloma
Drug: Pomalidomide
Drug: Feladilimab

Phase 1, Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Indianapolis, Indiana, United States and 58 other locations

Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic ma ...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin frozen liquid
Drug: Belantamab mafodotin lyophilized powder

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Indianapolis, Indiana, United States and 58 other locations

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to ide...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Indianapolis, Indiana, United States and 26 other locations

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to id...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Carfilzomib

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Indianapolis, Indiana, United States and 30 other locations

participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Modakafusp alfa

Phase 1, Phase 2

Takeda
Takeda

Noblesville, Indiana, United States and 94 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems